Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.

BACKGROUND: Tuberculosis remains one of the world's deadliest transmissible diseases despite widespread use of the BCG vaccine. MTBVAC is a new live tuberculosis vaccine based on genetically attenuated Mycobacterium tuberculosis that expresses most antigens present in human isolates of M tuberculosis. We aimed to compare the safety of MTBVAC with BCG in healthy adult volunteers. METHODS: We did this single-centre, randomised, double-blind, controlled phase 1 study at the Centre Hospitalier Universitaire Vaudois (CHUV; Lausanne, Switzerland). Volunteers were eligible for inclusion if they were aged 18-45 years, clinically healthy, HIV-negative and tuberculosis-negative, and had no history of active tuberculosis, chemoprophylaxis for tuberculosis, or BCG vaccination. Volunteers fulfilling the inclusion criteria were randomly assigned to three cohorts in a dose-escalation manner. Randomisation was done centrally by the CHUV Pharmacy and treatments were masked from the study team and volunteers. As participants were recruited within each cohort, they were randomly assigned 3:1 to receive MTBVAC or BCG. Of the participants allocated MTBVAC, those in the first cohort received 5 × 10(3) colony forming units (CFU) MTBVAC, those in the second cohort received 5 × 10(4) CFU MTBVAC, and those in the third cohort received 5 × 10(5) CFU MTBVAC. In all cohorts, participants assigned to receive BCG were given 5 × 10(5) CFU BCG. Each participant received a single intradermal injection of their assigned vaccine in 0·1 mL sterile water in their non-dominant arm. The primary outcome was safety in all vaccinated participants. Secondary outcomes included whole blood cell-mediated immune response to live MTBVAC and BCG, and interferon γ release assays (IGRA) of peripheral blood mononuclear cells. This trial is registered with ClinicalTrials.gov, number NCT02013245. FINDINGS: Between Jan 23, 2013, and Nov 6, 2013, we enrolled 36 volunteers into three cohorts, each of which consisted of nine participants who received MTBVAC and three who received BCG. 34 volunteers completed the trial. The safety of vaccination with MTBVAC at all doses was similar to that of BCG, and vaccination did not induce any serious adverse events. All individuals were IGRA negative at the end of follow-up (day 210). After whole blood stimulation with live MTBVAC or BCG, MTBVAC was at least as immunogenic as BCG. At the same dose as BCG (5×10(5) CFU), although no statistical significance could be achieved, there were more responders in the MTBVAC group than in the BCG group, with a greater frequency of polyfunctional CD4+ central memory T cells. INTERPRETATION: To our knowledge, MTBVAC is the first live-attenuated M tuberculosis vaccine to reach clinical assessment, showing similar safety to BCG. MTBVAC seemed to be at least as immunogenic as BCG, but the study was not powered to investigate this outcome. Further plans to use more immunogenicity endpoints in a larger number of volunteers (adults and adolescents) are underway, with the aim to thoroughly characterise and potentially distinguish immunogenicity between MTBVAC and BCG in tuberculosis-endemic countries. Combined with an excellent safety profile, these data support advanced clinical development in high-burden tuberculosis endemic countries. FUNDING: Biofabri and Bill & Melinda Gates Foundation through the TuBerculosis Vaccine Initiative (TBVI).

Genomic and transcriptomic analysis of the streptomycin-dependent Mycobacterium tuberculosis strain 18b.

The ability of Mycobacterium tuberculosis to establish a latent infection (LTBI) in humans confounds the treatment of tuberculosis. Consequently, there is a need to discover new therapeutic agents that can kill M. tuberculosis both during active disease and LTBI. The streptomycin-dependent strain of M. tuberculosis, 18b, provides a useful tool for this purpose since upon removal of streptomycin (STR) it enters a non-replicating state that mimics latency both in vitro and in animal models. The 4.41 Mb genome sequence of M. tuberculosis 18b was determined and this revealed the strain to belong to clade 3 of the ancient ancestral lineage of the Beijing family. STR-dependence was attributable to insertion of a single cytosine in the 530 loop of the 16S rRNA and to a single amino acid insertion in the N-terminal domain of initiation factor 3. RNA-seq was used to understand the genetic programme activated upon STR-withdrawal and hence to gain insight into LTBI. This revealed reconfiguration of gene expression and metabolic pathways showing strong similarities between non-replicating 18b and M. tuberculosis residing within macrophages, and with the core stationary phase and microaerophilic responses. The findings of this investigation confirm the validity of 18b as a model for LTBI, and provide insight into both the evolution of tubercle bacilli and the functioning of the ribosome.

Efecto dosis-respuesta de fracciones de Mycobacterium tuberculosis H37Rv sobre la expresión de las moléculas HLA-DR y B7 en monocitos humanos.

Tesis (Maestría en Ciencias con Especialidad en Inmunología) UANL

Efecto in vitro de diferentes dosis de Mycobacterium tuberculosis en la expresión de IL-1 de membrana y moléculas HLA-DR en macrófagos humanos

Tesis (Maestría en Ciencias con Especialidad en Inmunología) UANL

Análisis de la actividad de extractos crudos de Juglans regia L., Juglans mollis y Carya illinoensis contra mycobacterium tuberculosis

Tesis (Maestro en Ciencias con Especialidad en Química de Productos Naturales)

Actividad antimicobacteriana sobre Mycobacterium tuberculosis y

[Tesis] (Maestro en Ciencias con Especialidad en Microbiología) U.A.N.L.

Efecto de 150 subcultivos continuos sobre la composición genética y de virulencia de cepas de mycobacterium tuberculosis.

Tesis (Maestría en Ciencias con Acentuación en Microbiología) UANL, 2011.

Aislamiento y caracterización de compuestos derivados de plantas de la familia juglandaceae con efecto antimicrobiano sobre mycobacterium tuberculosis.

Tesis (Maestría en Ciencias con Acentuación en Química de productos Naturales) UANL, 2011.

Identificación de genes Vinculados con la Condición de resistencia a Fármacos de Primera Línea en Mycobacterium tuberculosis.

Tesis (Maestría en Ciencias con Acentuación en Microbiología) UANL, 2011.

Análisis de la resupuesta humoral contra la proteína Hspx de mycobacterium tuberculosis como biomarcador de tuberculosis latente.

Tesis (Maestría en Ciencias con Acentuación en Inmunobiología) UANL, 2012.

Aportaciones al mecanismo de acción del ácido mesodihidroguaiarético sobre mycobacterium tuberculosis H37Rv.

Tesis (Maestría en Ciencias con Orientación en Farmacia) UANL, 2013.

Secuenciación del genoma de una clona de mycobacterium tuberculosis resistente a todos los medicamentos antituberculosis de primera línea.

Tesis (Maestría en Ciencias con orientación en Biología Molecular e Ingeniería Genética) UANL, 2014.

Caracterización genética y evaluación de los genes de fosfolipasa C de Mycobacterium tuberculosis como factor de virulencia en una línea de macrófagos

Tesis ( Doctorado en Ciencias con Especialidad en Microbiología) UANL

Análisis genético y de virulencia de cepas de Mycobacterium tuberculosis sometidas a subcultivo

Tesis (Doctor en Ciencias con especialidad en Microbiología) U.A.N.L. Facultad de Ciencias Biológicas, 2007.